Trevi Therapeutics prices $100M common stock offering at $5.75 per share

Trevi Therapeutics, Inc.

Offering of 17.4M shares at $5.75/share; net proceeds ~$93.7M (~$107.8M if underwriters' option fully exercised).
Underwriters granted 30-day option to purchase up to 2.61M additional shares at the same price.
Proceeds to fund clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC.
Cash runway extended into 2029 based on current plans; additional capital needed for regulatory approval.
Offering expected to close on June 5, 2025; Morgan Stanley, Leerink, Stifel, Cantor as joint book-runners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.